Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges Review
| Authors: | Robert, S. M.; Toth, A.; Lev, S.; Bowden, S. G.; Yu, Y.; Imber, B. S.; Boire, A.; Drago, J. Z.; Modi, S.; Moss, N. S. |
| Review Title: | Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges |
| Abstract: | The management of brain metastases (BrM) remains a major clinical challenge due to limited drug delivery across the blood-brain barrier (BBB) and the need for simultaneous CNS and systemic disease management, often with competing therapeutic strategies. Antibody-drug conjugates (ADCs) are a promising class of drugs that offers precision therapy by combining the specificity of monoclonal antibodies with potent chemotherapeutics for targeted tumor delivery. This review explores the current landscape of ADCs in BrMs, challenges in BBB penetration, and CNS-specific toxicities, including interactions with radiotherapy and the risk of radiation necrosis. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025. |
| Keywords: | review; nonhuman; antineoplastic agents; brain tumor; brain neoplasms; antineoplastic agent; metastasis; radiotherapy; necrosis; central nervous system; monoclonal antibody; cancer inhibition; blood brain barrier; blood-brain barrier; brain metastasis; therapy; radiation necrosis; drug delivery system; pharmacokinetics; tumor microenvironment; antibody conjugate; immunoconjugates; systemic disease; commercial phenomena; human; antibody drug conjugate |
| Journal Title: | Journal of Neuro-Oncology |
| Volume: | 174 |
| Issue: | 3 |
| ISSN: | 0167-594X |
| Publisher: | Springer |
| Publication status: | Published |
| Date Published: | 2025-09-01 |
| Start Page: | 541 |
| End Page: | 556 |
| Language: | English |
| DOI: | 10.1007/s11060-025-05083-0 |
| PROVIDER: | scopus |
| PMCID: | PMC12263320 |
| PUBMED: | 40471420 |
| DOI/URL: | |
| Notes: | Review -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Nelson Moss -- Source: Scopus |
